An inducible caspase 9 safety switch for T-cell therapy

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Adoptive T-cell therapy shows promise for malignancies but faces challenges.
• Genetic modification of T cells can enhance efficacy but carries risks like oncogenesis and toxicity.
• A method to safely eliminate modified T cells in vivo is needed to address these concerns.

Purpose of the Study:

• To develop and validate a conditional "safety switch" for T cells.
• To ensure the safety switch does not impair T cell phenotype, function, or antigen specificity.
• To assess the efficiency and safety of the inducible caspase 9 system in eliminating modified T cells.

Main Methods:

• Engineered a modified human caspase 9 fused to FKBP for conditional dimerization.
• Expressed the safety switch in human T cells.
• Administered a synthetic dimerizer drug to induce apoptosis in transduced cells.
• Evaluated the system's efficacy in vitro and in vivo.

Main Results:

• The safety switch was stably and efficiently expressed in human T cells.
• The system did not impair T cell phenotype, function, or antigen specificity.
• A single low dose (10 nM) of dimerizer drug induced apoptosis in 99% of transduced cells.
• The system demonstrated low immunogenicity and selective elimination of T cells.

Conclusions:

• The inducible caspase 9 system provides a safe and efficient method for eliminating modified T cells.
• This safety switch has advantages over existing suicide genes, including low immunogenicity and targeted action.
• The system is suitable for incorporation into human T-cell therapies to enhance safety.